



# Financial calendar 2022 for FluoGuide, and release of the Q3 report 2021 is moved to 15<sup>th</sup> of November 2021

Copenhagen, Denmark, 5 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) releases financial calendar for 2022. The planned release of Q3 financial report 2021 is changed to 15<sup>th</sup> of November 2021

Financial calendar for 2022

Year-end report 2021 and Annual report 2021	30 March 2022
Annual General Meeting	18 May 2022
Q1 2022 report	31 May 2022
Q2 2022 report	25 August 2022
Q3 2022 report	24 November 2022

The planned release of the Q3 financial report 2021 is moved from 24<sup>th</sup> November to 15<sup>th</sup> November 2021.

## For further information, please contact:

Henrik Moltke, CFO  
FluoGuide A/S  
+45 22 44 54 04  
hm@fluoguide.com

## Certified Adviser:

Svensk Kapitalmarknadsgransking AB  
Phone: +46 70 755 95 51  
E-mail: ca@skmg.se

## About FluoGuide

FluoGuide's primary focus is to maximize surgical outcomes in oncology. The Company's lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide's products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient's chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is conducting a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma. FluoGuide is listed on Nasdaq First North Sweden under the ticker "FLUO".